Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2020 Results - Earnings Call Transcript

Aug. 12, 2020 11:54 AM ETAltimmune, Inc. (ALT) StockALT
SA Transcripts
153.96K Followers

Q2: 2020-08-11 Earnings Summary

EPS of -$0.94 misses by $0.66
 | Revenue of $721.64K (-55.62% Y/Y) misses by $628.36K

Altimmune, Inc. (NASDAQ:ALT) Q2 2020 Earnings Conference Call August 12, 2020 8:30 AM ET

Company Participants

Monique Kosse - IR, LifeSci Advisors
Vipin Garg - Chief Executive Officer
Scot Roberts - Chief Scientific Officer
Scott Harris - Chief Medical Officer
Will Brown - Chief Financial Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler
Jonathan Wolleben - JMP Securities

Operator

Greetings and welcome to the Altimmune Inc. Second Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host Ms. Monique Kosse, Investor Relations for Altimmune. You may begin.

Monique Kosse

Thank you, Melissa, and thank you everyone for participating in today's Q2 2020 earnings conference call. Leading the call today will be Dr. Vipin Garg, Chief Executive Officer of Altimmune. Also participating on the call today is Will Brown, Chief Financial Officer; Scot Roberts, Chief Scientific Officer; and Scott Harris, Chief Medical Officer. After the prepared remarks, we will open up the call for a question-and-answer session. A press release with the Q2 2020 financial results was issued last night and can be found on the Investors page of the company's website.

Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including those related to COVID-19 and its impact on our business operations, clinical trials and results of operations.

For a discussion of some of

Recommended For You

About ALT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ALT